HC Wainwright Analysts Give Trillium Therapeutics (TRIL) a $4.00 Price Target

Share on StockTwits

HC Wainwright set a $4.00 price target on Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report released on Friday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research raised Trillium Therapeutics from a hold rating to a buy rating and set a $0.75 target price for the company in a report on Thursday, April 25th.

TRIL stock opened at $0.63 on Friday. The company has a market cap of $13.38 million, a P/E ratio of -0.27 and a beta of 2.22. Trillium Therapeutics has a twelve month low of $0.51 and a twelve month high of $7.00.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.24. On average, equities analysts forecast that Trillium Therapeutics will post -1.92 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Trillium Therapeutics during the fourth quarter worth $35,000. Jane Street Group LLC acquired a new position in shares of Trillium Therapeutics during the fourth quarter worth $43,000. Oxford Asset Management LLP increased its position in shares of Trillium Therapeutics by 64.0% during the first quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 36,534 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Trillium Therapeutics by 25.2% during the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares in the last quarter. 27.22% of the stock is owned by institutional investors and hedge funds.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Further Reading: What is the downside to momentum investing?

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$603.70 Million in Sales Expected for ConturaEnergyInc   .  This Quarter
$603.70 Million in Sales Expected for ConturaEnergyInc . This Quarter
Analysts Anticipate Verisign, Inc.  Will Post Quarterly Sales of $306.45 Million
Analysts Anticipate Verisign, Inc. Will Post Quarterly Sales of $306.45 Million
J2 Global Inc  Expected to Post Quarterly Sales of $318.47 Million
J2 Global Inc Expected to Post Quarterly Sales of $318.47 Million
$2.69 Billion in Sales Expected for Iqvia Holdings Inc  This Quarter
$2.69 Billion in Sales Expected for Iqvia Holdings Inc This Quarter
Zacks: Analysts Anticipate CarMax, Inc  Will Announce Quarterly Sales of $5.22 Billion
Zacks: Analysts Anticipate CarMax, Inc Will Announce Quarterly Sales of $5.22 Billion
Zacks: Analysts Anticipate Papa John’s Int’l, Inc.  Will Post Quarterly Sales of $396.88 Million
Zacks: Analysts Anticipate Papa John’s Int’l, Inc. Will Post Quarterly Sales of $396.88 Million


© 2006-2019 Ticker Report